These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1869342)

  • 21. Pharmacokinetics of clodronate in renal failure.
    Saha H; Castren-Kortekangas P; Ojanen S; Juhakoski A; Tuominen J; Tokola O; Pasternack A
    J Bone Miner Res; 1994 Dec; 9(12):1953-8. PubMed ID: 7872061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of practolol elimination in all grades of chronic renal failure.
    Kaye CM; Kumana CR; Franklin DA; Baker LR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):83-8. PubMed ID: 1165145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colchicine disposition in patients with familial Mediterranean fever with renal impairment.
    Ben-Chetrit E; Scherrmann JM; Zylber-Katz E; Levy M
    J Rheumatol; 1994 Apr; 21(4):710-3. PubMed ID: 8035398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigations on the pharmacokinetics of pentoxifylline in chronic renal failure (authors transl)].
    Schaefer K; von Herrath D; Hensel A; Grigoleit HG
    Med Klin; 1977 Feb; 72(6):204-6. PubMed ID: 840136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Cytembena in chronic renal impairment.
    Schück O; Grafnetterová J; Sotorník I
    Neoplasma; 1976; 23(2):161-70. PubMed ID: 947088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of iopentol in patients with chronic renal failure.
    Svaland MG; Kolmannskog F; Lillevold PE; Nordal KP; Ressem L; Berg KJ
    Acta Radiol; 1992 Sep; 33(5):482-4. PubMed ID: 1389660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral flecainide pharmacokinetics in patients with impaired renal function.
    Forland SC; Burgess E; Blair AD; Cutler RE; Kvam DC; Weeks CE; Fox JM; Conard GJ
    J Clin Pharmacol; 1988 Mar; 28(3):259-67. PubMed ID: 3129455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency.
    de Mey C; Sułowicz W; Stompór T; Ezan E; Retzow A; Althaus M
    Arzneimittelforschung; 2003; 53(11):769-73. PubMed ID: 14677372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
    Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of Lidaprim in cases of impaired renal function.
    Hitzenberger G; Korn A; Pichler H; Bonelli J; Magometschnigg D
    Int J Clin Pharmacol Biopharm; 1977 Jul; 15(7):310-4. PubMed ID: 892947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of renal impairment on the pharmacokinetics of zalcitabine.
    Bazunga M; Tran HT; Kertland H; Chow MS; Massarella J
    J Clin Pharmacol; 1998 Jan; 38(1):28-33. PubMed ID: 9597556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine.
    Pfeffer M; Gaver RC; Ximenez J
    Antimicrob Agents Chemother; 1983 Dec; 24(6):915-20. PubMed ID: 6660858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
    Mallikaarjun S; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between renal function and disposition of oral cefixime.
    Dhib M; Moulin B; Leroy A; Hameau B; Godin M; Johannides R; Fillastre JP
    Eur J Clin Pharmacol; 1991; 41(6):579-83. PubMed ID: 1815970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Elimination kinetics and dosage of digoxin in patients in renal failure (author's transl)].
    Ohnhaus EE; Spring P; Dettli L
    Dtsch Med Wochenschr; 1974 Sep; 99(37):1797-803. PubMed ID: 4457307
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function.
    Konishi K; Suzuki H; Hayashi M; Saruta T
    J Antimicrob Chemother; 1993 Mar; 31(3):413-20. PubMed ID: 8486575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function.
    Foote EF; Lee DR; Karim A; Keane WF; Halstenson CE
    J Clin Pharmacol; 1995 Apr; 35(4):384-9. PubMed ID: 7650228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.